0001209191-21-049123.txt : 20210802 0001209191-21-049123.hdr.sgml : 20210802 20210802192735 ACCESSION NUMBER: 0001209191-21-049123 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210729 FILED AS OF DATE: 20210802 DATE AS OF CHANGE: 20210802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Imran Talat CENTRAL INDEX KEY: 0001869579 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40672 FILM NUMBER: 211137386 MAIL ADDRESS: STREET 1: C/O RANI THERAPEUTICS HOLDINGS, INC. STREET 2: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001856725 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 BUSINESS PHONE: (408) 457-3700 MAIL ADDRESS: STREET 1: 2051 RINGWOOD AVENUE CITY: SAN JOSE STATE: CA ZIP: 95131 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2021-07-29 2021-07-29 0 0001856725 Rani Therapeutics Holdings, Inc. RANI 0001869579 Imran Talat C/O RANI THERAPEUTICS LLC 2051 RINGWOOD AVE. SAN JOSE CA 95131 1 1 0 0 Chief Executive Officer Class A Common Stock 829435 I See footnote Class A Common LLC Units Class A Common Stock 43421 D Stock Option (Right to Buy) 9.45 2031-07-28 Class A Common Stock 78877 D This amendment is being filed to correctly reflect the shares held directly and indirectly. Represents 378,533 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 450,902 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Represents Class A Common LLC Units of Rani Therapeutics, LLC, a direct subsidiary of the Issuer. The Class A Common LLC Units are exchangeable for shares of Class A Common Stock on a one-for-one basis at the discretion of the holder, subject to certain exceptions, conditions and adjustments, and have no expiration date. The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021. This amendment is being filed to correctly reflect the exercise price of the Stock Option. /s/ Josh Seidenfeld, Attorney-in-Fact for Talat Imran 2021-08-02